|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
over 100 countries
|
|
gptkbp:age
|
approved for ages 6 months and older (varies by country)
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2020
|
|
gptkbp:ATCCode
|
gptkb:J07BX03
|
|
gptkbp:boosterInterval
|
at least 5 months after primary series
|
|
gptkbp:boosters
|
yes
|
|
gptkbp:brand
|
gptkb:Comirnaty
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contains
|
gptkb:plastic
sodium chloride
potassium chloride
sucrose
cholesterol
lipid nanoparticles
dibasic sodium phosphate dihydrate
monobasic potassium phosphate
nucleoside-modified mRNA
|
|
gptkbp:containsAdjuvant
|
no
|
|
gptkbp:containsPreservative
|
no
|
|
gptkbp:developedBy
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:dosingSchedule
|
two doses, 3 weeks apart (primary series)
|
|
gptkbp:efficacyAgainstOriginalStrain
|
~95%
|
|
gptkbp:emergencyServices
|
granted in multiple countries
|
|
gptkbp:firstCountryApproved
|
gptkb:United_Kingdom
|
|
gptkbp:form
|
suspension for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tozinameran
|
|
gptkbp:indication
|
prevention of COVID-19
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:patent
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:pregnancyCategory
|
consult healthcare provider
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
anaphylaxis
chills
myocarditis
injection site pain
|
|
gptkbp:storage
|
-70°C
|
|
gptkbp:target
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:technology
|
lipid nanoparticle delivery
|
|
gptkbp:vaccineType
|
gptkb:gene
|
|
gptkbp:WHO_EUL
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Comirnaty
|
|
gptkbp:bfsLayer
|
5
|